Begin main content

Difluoromethylornithine for the Treatment of Neuroblastoma in the Pediatric Population: Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Last updated: October 5, 2018
Project Number: RA0971-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Reference List
Result type: Report

Question

  1. What is the clinical effectiveness of difluoromethylornithine (DFMO) for the treatment or preventative treatment of neuroblastoma in the pediatric population?
  2. What is the cost-effectiveness of difluoromethylornithine (DFMO) for the treatment or preventative treatment of neuroblastoma in the pediatric population?
  3. What are the evidence-based guidelines associated with the use of difluoromethylornithine (DFMO) for the treatment or preventative treatment of neuroblastoma in the pediatric population?

Key Message

One non-randomized study was identified regarding difluoromethylornithine (DFMO) for the treatment of prevention of neuroblastoma in the pediatric population.